Table 1 Ongoing international clinical trials of PD-1 and PD-L1 inhibitors on lung cancer with participating Chinese centers
From: Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
Indentifier | Drugs | Location(s) | Phase | Indication | Population | Status in China |
|---|---|---|---|---|---|---|
NCT02220894 KEYNOTE 042 | Pembrolizumab | International | III | First-line | Advanced or metastatic NSCLC, EGFR and ALK wild-type, PD-L1-positive | Closed |
NCT03003962 − | Durvalumab | Asia (16/32) | III | First-line | Advanced NSCLC, EGFR and ALK wild-type, PD-L1-high expression | Recruiting |
NCT02542293 NEPTUNE | Durvalumab D + T | International | III | First-line | Advanced or metastatic, NSCLC, EGFR and ALK wild-type | Recruiting |
NCT02409342 IMpower110 | Atezolizumab | International | III | First-line | Chemotherapy-naïve and stage IV NSCLC, PD-L1-positive | Not yet recruiting |
NCT02763579 IMpower133 | Atezolizumab A + C + E | International | I/III | First-line | Extensive-stage SCLC | Recruiting |
NCT02657434 IMpower132 | Atezolizumab A + C + P | International | III | First-line | Chemotherapy-naïve and stage IV non-squamous NSCLC | Not yet recruiting |
NCT02613507 CheckMate078 | Nivolumab | Asia (23/32) | III | Second-line and beyond | Stage IIIB/IV or recurrent NSCLC after failure with platinum-containing doublet chemotherapy | Closed |
NCT02864394 MK-3475-033 | Pembrolizumab | International | III | Second-line and beyond | Stage IIIB/IV or recurrent NSCLC after failure with platinum-containing chemotherapy, PD-L1-positive, no EGFR sensitizing mutation | Recruiting |
NCT02481830 CheckMate331 | Nivolumab | International | III | Second-line | Relapsed SCLC after platinum-based first-line chemotherapy | Not yet recruiting |
NCT02813785 IMpower 210 | Atezolizumab | Asia (27/40) | III | Second-line and beyond | NSCLC after failure with platinum-containing chemotherapy | Recruiting |
NCT02486718 IMpower 010 | Atezolizumab | International | III | Adjuvant therapy | Stage IB–IIIA NSCLC following resection and adjuvant chemotherapy | Recruiting |
NCT02273375 BR.31 | Durvalumab | International | III | Adjuvant therapy | Completely resected stage IB–IIIA NSCLC | Recruiting |
NCT02835690 KEYNOTE 032 | Pembrolizumab | China | I | – | Locally advanced or metastatic NSCLC | Not yet recruiting |
NCT02978482 – | Durvalumab D + T | China | I | – | Advanced malignancies | Recruiting |